Navigation Links
EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board
Date:9/2/2010

img src='http://server.iad.liveperson.net/hc/23818417/?cmd=repstate&site=23818417&&ver=1&imageUrl=http://content.prnewswire.com/designimages&skill=PRN' id="chatimage" border="0" style="display:none;" > --> Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board

 

VIENNA, Austria, September 2, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes announced today the appointment of two seasoned biotechnology executives to its Advisory Board. The new appointees are Dr. David Rozzell, founder of BioCatalytics (now Codexis) and currently CEO of Solidus Biosciences, and Dr. Ulf Bethke, COO of Miltenyi Biotec. Dr. Thomas Moser, Pontis Capital, and Harald Schuerz, Wiener Wachstumsfonds, will continue to serve on the realigned Advisory Board.

With its current members, EUCODIS Bioscience's Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, stre
'/>"/>

SOURCE EUCODIS Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
2. EUCODIS Bioscience Appoints Thomas Fischer as New CEO
3. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
4. EUCODIS Bioscience Launches Lipase Portfolio
5. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
6. EUCODIS Bioscience Signs Research Agreement With Genencor
7. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
8. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
9. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
10. Signum Biosciences Names Braham Shroot as Chief Executive Officer
11. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... - Injured soldiers in Iraq and Afghanistan are becoming ... a Madison-based company is developing counter-measures. , ,With a ... U.S. Army in hand, ConjuGon, Inc. ... antibiotic-resistant bacterial infections. , ,"We are pleased that the ...
... White Sox this year and as for the Cubs ... What we cannot "wait until next year" for is some real ... Chicago. , ,There should be as much buzz, if not more, ... teams that didn't even make the playoffs, but maybe the media ...
... - Patent law is esoteric territory, but a Madison court ... in the process it might be giving smaller drug companies ... , ,The most recent example occurred last month. After a ... jury in U.S. District Court for the Western District ...
Cached Biology Technology:Wait `till next year OK for baseball, not broadband 2Wait `till next year OK for baseball, not broadband 3Wait `till next year OK for baseball, not broadband 4Wait `till next year OK for baseball, not broadband 5With patents, Wisconsin court gaining reputation as a "rocket docket" 2With patents, Wisconsin court gaining reputation as a "rocket docket" 3With patents, Wisconsin court gaining reputation as a "rocket docket" 4
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... cellsas indicated by a molecular imaging techniquecould tell researchers ... headaches and psychosis in schizophrenic patients, occur and provide ... two studies published in the November issue of the ... positron emission tomography (PET)a noninvasive molecular imaging techniqueresearchers were ...
... When 100 m sprinters launches themselves from the starting blocks, ... few strides. Acceleration through the first few strides is the ... by an American football star, who sprints in his position ... his technique and training regime, Piazza decided to focus on ...
... have confirmed that the largest bat in Europe, ... the Late Pleistocene (between 120,000 and 10,000 years ago). ... at Abrc Roman (Barcelona) prove that this bat had ... than it does today, having declined due to the ...
Cached Biology News:Unlocking mysteries of the brain with PET 2Short heels make elite sprinters super speedy 2The largest bat in Europe inhabited northeastern Spain more than 10,000 years ago 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: